Identification and Characterization of ISOC2 as A Potential Drug Target and Biomarker

Target Name: ISOC2

NCBI ID: G79763

ISOC2

Other Name(s): ISOC2 variant 2 | Isochorismatase domain-containing protein 2 | Isochorismatase domain containing 2, transcript variant 2 | isochorismatase domain-containing protein 2, mitochondrial | isochorismatase domain containing 2 | ISOC2_HUMAN | Isochorismatase domain-containing protein 2 (isoform 2) | Isochorismatase domain containing 2 | Isochorismatase domain-containing protein 2, mitochondrial

Identification and Characterization of ISOC2 as A Potential Drug Target and Biomarker

The identification and characterization of potential drug targets and biomarkers is a crucial aspect of drug development. drug targets are molecules that are involved in the pathogenesis of a disease and are targeted by drugs to induce therapeutic effects. Biomarkers are molecules that are derived from the body and can be used as indicators of the presence or absence of a disease or the level of a disease. ISOC2 (ISOC2 variant 2) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases , and autoimmune diseases.

Structure and Function

ISOC2 is a protein that is expressed in a variety of tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the insulin secretion secretion protein (ISSP) family and is responsible for the production and secretion of insulin . ISOC2 is a 21-kDa protein that consists of two distinct domains: an N-terminal transmembrane domain and a C-terminal cytoplasmic domain.

The N-terminal transmembrane domain of ISOC2 is characterized by a single pass of the extracellular domain through the cell membrane and is responsible for the formation of the N-end rule (NER) domain. The NER domain is known for its ability to interact with various signaling molecules, including thyroid hormone, growth factors, and neurotransmitters. This domain is also involved in the regulation of cellular signaling pathways, including the insulin signaling pathway.

The C-terminal cytoplasmic domain of ISOC2 is characterized by a single alpha-helix and is responsible for the formation of a nucleotide-binding oligomerization (NBO) domain. The NBO domain is known for its ability to interact with various DNA-binding proteins, including p53, and is involved in the regulation of gene expression.

Expression and Regulation

ISOC2 is expressed in a variety of tissues throughout the body and is involved in the regulation of insulin secretion, as well as the regulation of cellular signaling pathways. It is highly expressed in the pancreas, where it is involved in the regulation of insulin secretion by the pancreatic beta-cells. ISOC2 is also expressed in other tissues, including the brain, where it is involved in the regulation of insulin sensitivity and the development of neurodegenerative diseases.

ISOC2 is regulated by various signaling pathways, including the insulin signaling pathway. This pathway is activated by the presence of insulin and results in the release of insulin from the pancreatic beta-cells. The insulin signal transduction pathway is regulated by several factors, including the N-terminal transmembrane domain of ISOC2. This domain is involved in the interaction with various signaling molecules, including thyroid hormone, growth factors, and neurotransmitters.

ISOC2 is also regulated by the C-terminal NBO domain. This domain is known for its ability to interact with various DNA-binding proteins, including p53. This interaction between ISOC2 and p53 results in the regulation of gene expression, including the expression of genes involved in the regulation of insulin sensitivity and the development of neurodegenerative diseases.

Drug Targeting

ISOC2 is a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The N-terminal transmembrane domain of ISOC2 is involved in the regulation of cellular signaling pathways, including the insulin signaling pathway, and may be a potential target for drugs that can modulate this pathway. The C-terminal NBO domain is involved in the regulation of gene expression and may be a potential target for drugs that can modulate this domain.

In addition to its potential as a drug target, ISOC2 is also a potential biomarker for a variety of diseases. The N-terminal transmembrane domain of ISOC2 is known to interact with various signaling

Protein Name: Isochorismatase Domain Containing 2

The "ISOC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ISOC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets